FDA to consider BMS’ Orencia for graft versus host disease

3 years ago

by David Miller

951 Views

Leukaemia patients who receive stem cell transplant may gain access to Orencia by the end of the year

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!